Diabetic Neuropathy Market Trends

  • Report ID: 4526
  • Published Date: Sep 10, 2025
  • Report Format: PDF, PPT

Diabetic Neuropathy Market Growth Drivers and Challenges:

Growth Drivers

  • Rising Improper Diet in People with Increasing Preference for Outdoor Food and Disposable Income – Consuming unhealthy foods such as sugary drinks, processed and fried foods leads to weight gain, obesity, and the development of chronic diseases. Also, eating an unhealthy diet leads to disorders including cardiovascular diseases, cancer, communicable and non-communicable diseases, and infections. All these elements are estimated to boost market growth. As per the data collected, obesity affected over 750 million adults across the world in 2020
  • Rising Population Rates with Increasing Living Standards and Longevity – Increasing population is expected to increase the incidence of diabetic cases among the people, and it is expected to drive the market’s growth in the upcoming year. As per the reported data, the world population increased to 7.8 billion in 2021 up from 7.3 billion in 2015.
  • Increasing Practice of a Sedentary Lifestyle that Leads to Weight Gain Issues - Approximately 3.2 million deaths and 32.1 million DALYs (representing about 2.1% of global DALYs) each year are caused by insufficient physical activity.
  • Rising Awareness Regarding Diagnosis and Treatment Among People – It was observed that 1.5 million new diabetic cases were diagnosed in 2018 in the U.S.

Challenges

  • High Cost of Treatment for Neuropathic Pain - The market's future is being hampered by the rising cost of the medications used to treat diabetic neuropathy market. The availability of alternate treatments, such as radiotherapy and physiotherapy, appears to be more convenient and results in better clinical outcomes for the patients. As per recent data, pharmacological therapy expenses each year and over the course are considered USD 13.80 for expert consultations and USD 10.50 for general practitioners.
  • Undiagnosed Cases of Diabetes
  • Lack of Access to People for Proper Medical Care

Base Year

2025

Forecast Period

2026-2035

CAGR

6.4%

Base Year Market Size (2025)

USD 4.84 Billion

Forecast Year Market Size (2035)

USD 9 Billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of diabetic neuropathy is evaluated at USD 5.12 Billion.

The global diabetic neuropathy market size was worth around USD 4.84 Billion in 2025 and is set to register a CAGR of more than 6.4%, exceeding USD 9 Billion revenue by 2035.

North America diabetic neuropathy market will hold over 38.8% share by 2035, driven by rising diabetes prevalence and healthcare expenditure.

Key players in the market include Hoffmann-La Roche Ltd., Abbott Laboratories, Eli Lilly and Company, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Lupin Limited, Glenmark Pharmaceuticals Limited, Assertio Holdings, Inc., Astellas Pharma US, Inc., Pfizer Inc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos